SARS-CoV-2
Showing 1 - 25 of 246
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
Recruiting
- SARS-CoV-2
- SPIKEVAX
-
New York, New YorkAetion, Inc
Nov 8, 2023
Booster Dose of Comirnaty in Children Ages 6 Months Though 4
Not yet recruiting
- SARS-CoV-2
- COVID-19
- COMIRNATY intramuscular injection
-
Tokyo, JapanPfizer Local Country
Nov 8, 2023
SARS-CoV-2, Prevention Trial in Chongqing (A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray, A8G6 SARS-CoV-2
Recruiting
- SARS-CoV-2
- Prevention
- A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray
- A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient
-
Chongqing, Chongqing, ChinaThe Second Affiliated Hospital of Chongqing Medical University
Nov 9, 2023
SARS-CoV-2, Influenza Trial in Canada, United States (mRNA-1083, Placebo, Influenza Vaccine)
Not yet recruiting
- SARS-CoV-2
- Influenza
- mRNA-1083
- +3 more
-
Anniston, Alabama
- +172 more
Oct 18, 2023
SARS-CoV-2, Prevention Trial in Chongqing (MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray, Placebo Comparator: MY-586
Recruiting
- SARS-CoV-2
- Prevention
- MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray
- Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient
-
Chongqing, Chongqing, ChinaThe Second Affiliated Hospital of Chongqing Medical University
Aug 2, 2023
SARS-CoV-2 Trial (CV0701 Bivalent High dose, CV0701 Bivalent Medium dose, CV0701 Bivalent Low dose)
Not yet recruiting
- SARS-CoV-2
- CV0701 Bivalent High dose
- +4 more
- (no location specified)
Jul 24, 2023
COVID 19 Disease, Mild to Moderate COVID 19 Disease, SARS-CoV-2 Trial (Tafenoquine Oral Tablet, Placebo)
Not yet recruiting
- COVID 19 Disease
- +4 more
- Tafenoquine Oral Tablet
- Placebo
- (no location specified)
Jul 13, 2023
SARS-CoV-2 Trial in Nanjing (SARS-CoV-2 Bivalent mRNA Vaccine, Recombinant SARS-CoV-2 vaccine, Saline)
Not yet recruiting
- SARS-CoV-2
- SARS-CoV-2 Bivalent mRNA Vaccine
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Disease Control and Prevention
Jul 7, 2023
SARS-CoV-2 Trial in Nanjing (SARS-CoV-2 Bivalent mRNA Vaccine, Saline)
Not yet recruiting
- SARS-CoV-2
- SARS-CoV-2 Bivalent mRNA Vaccine
- Saline
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Disease Control and Prevention
Jul 7, 2023
SARS-CoV, SARS-CoV-2 Trial in Durban, Soweto (VXCO-100, COVID-19 mRNA vaccine and VXCO-100, COVID-19 mRNA vaccine)
Not yet recruiting
- SARS-CoV
- SARS-CoV-2
- VXCO-100
- +2 more
-
Durban, South Africa
- +1 more
Jul 5, 2023
A Study of the Effectiveness of Moderna COVID-19 Vaccine
Recruiting
- SARS-CoV-2
- COVID-19
- mRNA-1273
-
Pasadena, CaliforniaKaiser Permanente Southern California
Jul 5, 2023
SARS-CoV-2 Trial in Chengdu (RBMRNA-176, Placebo)
Active, not recruiting
- SARS-CoV-2
- RBMRNA-176
- Placebo
-
Chengdu, Sichuan, ChinaChengdu Xinhua Hospital affiliated to North Sichuan Medical Coll
Jun 12, 2023
SARS-CoV-2 Trial in Chengdu (SARS-CoV-2 mRNA vaccine (RBMRNA), CoronaVac®)
Active, not recruiting
- SARS-CoV-2
- SARS-CoV-2 mRNA vaccine (RBMRNA)
- CoronaVac®
-
Chengdu, Sichuan, ChinaChengdu Xinhua Hospital affiliated to North Sichuan Medical Coll
Jun 12, 2023
Japan of Shock and Anaphylaxis After Severe Acute Respiratory
Active, not recruiting
- SARS-CoV-2
-
Tokyo, JapanCMIC Co., Ltd.
Jun 5, 2023
Japan After Severe Acute Respiratory Syndrome Coronavirus 2
Not yet recruiting
- SARS-CoV-2
-
Tokyo, JapanCMIC Co., Ltd
Jun 6, 2023
Severe Exacerbation of Severe Acute Respiratory Syndrome
Active, not recruiting
- SARS-CoV-2
-
Tokyo, JapanCMIC Co. Ltd.,
Jun 5, 2023
Optical Quality During the Peak of the Covid-19 Pandemic
Completed
- Corneal Wavefront Aberration
- SARS-CoV-2
-
Tianjin, Tianjin, ChinaTianjin Eye Hospital
May 27, 2023
COVID-19 Vaccines Using Information From California State
Not yet recruiting
- SARS-CoV-2
- +2 more
- Pfizer-BioNTech COVID-19 bivalent mRNA vaccine
- (no location specified)
May 23, 2023
COVID-19, SARS-CoV-2 Trial in Seoul (QTP104 1ug, QTP104 5ug, QTP104 25ug)
Active, not recruiting
- COVID-19
- SARS-CoV-2
- QTP104 1ug
- +2 more
-
Seoul, Korea, Republic of
- +1 more
May 24, 2023
SARS-CoV, SARS-CoV-2 Trial in Decatur, Baltimore, Rochester (VXCO-100)
Recruiting
- SARS-CoV
- SARS-CoV-2
- VXCO-100
-
Decatur, Georgia
- +2 more
May 19, 2023
SARS-CoV-2, Influenza Trial in United States (Fluarix, mRNA-1083.1, mRNA-1083.2)
Recruiting
- SARS-CoV-2
- Influenza
- Fluarix
- +8 more
-
Chandler, Arizona
- +68 more
Apr 24, 2023
SARS-CoV-2 Trial in Islamabad (SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution)
Recruiting
- SARS-CoV-2
- SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)
- 0.9% sodium chloride solution
-
Islamabad, PakistanSindh Infectious Diseases Hospital & Research Center Dow Univers
Apr 16, 2023